Novo Nordisk's REDEFINE trials test CagriSema for weight and heart health in adults with type 2 diabetes and/or obesity. Participate and shape diabetes care.

Research shows screening children ages 2-6 best predicts childhood type 1 diabetes. Early screening also leads to more timely treatment, better outcomes, and reduced...

Uncover phase 2 clinical trial results of CagriSema, a promising diabetes treatment showing improvements in A1C, weight loss, and time in range.

Pfizer propels clinical trials for danuglipron, a novel oral GLP-1 medication for obesity and type 2 diabetes, with promising preliminary results for A1C and weight loss.

Explore the role of artificial intelligence in diabetic retinopathy detection with Eyenuk's innovative technology. Here we also examine the disputed effects of GLP-1s on...

At the 17th annual Diabetes Forum at ADA 2023, the diaTribe Foundation and TCOYD moderated an expert panel that discussed access and equity issues, breakthrough...

A lot has happened this year advancing time in range as a primary glucose metric in diabetes care globally. Though we aren’t there yet, a panel shared their thoughts on...

Clinical trial participants taking retatrutide for obesity experienced an average of 24% in body weight reduction over 48 weeks. Lead scientists shared their findings at...

PIONEER PLUS and OASIS 1 trials show high-dose Rybelsus significantly reduces A1C and promotes weight loss in type 2 diabetes and obesity patients.

Clinical trial results have shown that once-weekly basal insulins are just as effective at reducing A1C as once-daily insulin.

Results from a recent clinical trial showed the new medication survodutide may be a useful treatment tool for weight loss. People with overweight or obesity on the...

end Uncover SURMOUNT-2 trial's outcomes: Tirzepatide's promise for weight loss, better blood sugar, and improved cardiometabolic health in type 2 diabetes.

Join diaTribe at the American Diabetes Association's 83rd scientific conference for insights on future diabetes care, medication, and the latest tech. Plus, explore...

New findings from the DiRECT trial reveal that weight loss can lead to type 2 diabetes remission. Learn about the benefits of a low-calorie diet and support in diabetes...

Reduce heart failure risk with FDA-approved Inpefa (sotagliflozin). Inhibiting SGLT-2 and SGLT-1, it outshines other medications. Learn more about its effectiveness and...

Oculis' OCS-01 eye drops show promising results in phase 3 trials for diabetic macular edema treatment. Uncover a potential revolution in non-invasive eye care solutions.

This clinical trial is currently recruiting – participants will be enrolled in one of two stress-intervention courses to measures changes in A1C, diabetes distress, and...

Participate in Omada Health's 6-month online study for type 2 diabetes management. Earn up to $250, experience their program, and contribute to diabetes research – all...

Early-stage study results show that a new one-hour intestinal procedure called ReCET may be able to help people with type 2 diabetes improve their blood sugars enough to...

The FDA recently cleared a new experimental drug for type 1 diabetes to begin a phase 2 clinical trial. If approved, the drug would be the first therapy to specifically...